Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

furzah Oct. 7 at 8:02 AM

$AUTL LUPUS is not curable, but CAR-T can cure almost everyone. This disease mainly affects adults between 20 and 40 years of age. https://www.springermedizin.de/car-t-zellen/systemischer-lupus-erythematodes/langzeitverlauf-von-effizienz-und-sicherheit-der-cd19-car-t-zell/51423438 100s Billion Dollar market will be developed. EXTREME

0 · Reply

gandolf63 Oct. 6 at 10:18 PM

$AUTL 53 treatment centers are open LG

0 · Reply

wussel Oct. 6 at 6:09 PM

$AUTL I am sure there were also big investors selling AMD positions completely when the stock hovered around 4 $ for years. Just because it is a big fund does not mean they can look into the future or are always right

2 · Reply

Ycapital Oct. 6 at 5:37 PM

$AUTL looking at $SPRB sitting with AUTL

0 · Reply

keypatience Oct. 6 at 5:29 PM

$AUTL Thx for this very important info. I did not thought they would sell their shares completely. It makes sense why the share price went so much down.

0 · Reply

Michael_garic Oct. 6 at 5:24 PM

$AUTL

0 · Reply

Michael_garic Oct. 6 at 5:21 PM

$AUTL Wellington has over 1 Trillion is assets under management so although a big stake in AUTL, a small overall position

1 · Reply

Imatron12 Oct. 6 at 5:18 PM

$AUTL I sold my TSLA shares and put it back into AUTL

0 · Reply

BRLondon Oct. 6 at 5:10 PM

$AUTL There may be a million reasons for a fund to liquidate a position, they dropped the price to 1.40-1.50 for new buyers to be happy to absorb, so now that that is done, this area is a great support where new institutional investors have built heir base, looking to sell at much higher prices.

1 · Reply

Joe_90_ Oct. 6 at 5:05 PM

$AUTL thank you for the shares

0 · Reply

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 5:26 PM EDT - 7 weeks ago

Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable

Aug 12, 2025, 4:37 PM EDT - 7 weeks ago

Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 7 weeks ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 2 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 2 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jul 15, 2025, 4:05 PM EDT - 2 months ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2025, 2:00 AM EDT - 4 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 6, 2025, 11:09 AM EDT - 4 months ago

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

May 29, 2025, 4:05 PM EDT - 4 months ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 4 months ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 20, 2025, 5:47 AM EDT - 4 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC CAPR CLPT EDIT NTLA VANI VERV

May 14, 2025, 9:30 AM EDT - 5 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 11, 2025, 4:22 AM EDT - 5 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 5 months ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 5 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 5 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 11:55 AM EDT - 7 months ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 7 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 4, 2025, 10:21 AM EST - 7 months ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Jan 17, 2025, 7:00 AM EST - 9 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 10 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 12:16 AM EST - 11 months ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 12, 2024, 2:57 PM EST - 11 months ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 11 months ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Sep 6, 2024, 2:12 PM EDT - 1 year ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Aug 10, 2024, 12:05 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

May 31, 2024, 8:00 AM EDT - 1 year ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 12:55 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

May 17, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 1:02 PM EDT - 1 year ago

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 15, 2024, 5:23 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Feb 29, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 8, 2024, 7:00 AM EST - 1 year ago

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 5:45 AM EST - 1 year ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 6, 2024, 9:52 AM EST - 1 year ago

Autolus Upgrades Leadership And Faces CAR-T Approval

Jan 23, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces publication in ACS Chemical Biology

$Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)$

Jan 22, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

furzah Oct. 7 at 8:02 AM

0 · Reply

gandolf63 Oct. 6 at 10:18 PM

$AUTL 53 treatment centers are open LG

0 · Reply

wussel Oct. 6 at 6:09 PM

2 · Reply

Ycapital Oct. 6 at 5:37 PM

$AUTL looking at $SPRB sitting with AUTL

0 · Reply

keypatience Oct. 6 at 5:29 PM

$AUTL Thx for this very important info. I did not thought they would sell their shares completely. It makes sense why the share price went so much down.

0 · Reply

Michael_garic Oct. 6 at 5:24 PM

$AUTL

0 · Reply

Michael_garic Oct. 6 at 5:21 PM

$AUTL Wellington has over 1 Trillion is assets under management so although a big stake in AUTL, a small overall position

1 · Reply

Imatron12 Oct. 6 at 5:18 PM

$AUTL I sold my TSLA shares and put it back into AUTL

0 · Reply

BRLondon Oct. 6 at 5:10 PM

1 · Reply

Joe_90_ Oct. 6 at 5:05 PM

$AUTL thank you for the shares

0 · Reply

TricksterT Oct. 6 at 4:38 PM

$AUTL

1 · Reply

RonIsWrong Oct. 6 at 4:36 PM

$AUTL you were right Wellington is completely out. 27M shares

4 · Reply

wussel Oct. 6 at 1:47 PM

$AUTL Week of October 20th will be interesting: 1. NICE decision on Ocotober 23rd 2. Phase 1 SLN update between October 24th and 26th

1 · Reply

JessTaylor22 Oct. 4 at 10:10 PM

$AUTL @RonIsWrong How is your wife doing, Sir?

1 · Reply

Vikingsstrade Oct. 4 at 5:55 PM

$AUTL $MIND $VEEV $SO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

Casiel Oct. 4 at 3:12 AM

$AUTL

1 · Reply

SouthernItUp Oct. 4 at 1:59 AM

$AUTL Volume in September was nearly twice the next highest month’s volume. Which was August. 👀

2 · Reply

alexpitti Oct. 3 at 11:23 PM

another 2 weeks in the books. i have an ear infection, but i should be healthy in 2-3 days huge data from $AUTL coming in october huge approvals for $STXS in October GenesisX & EMAGIN 5F & MAGiC Sweep ESMO in 2 weeks for $DCTH hopefully we can get the first procedure announced next week $ABEO kinda in no man's land right now

3 · Reply

TricksterT Oct. 3 at 8:10 PM

$AUTL algos keeping it contained but $1.57 recent support looks nice.

0 · Reply

Ycapital Oct. 3 at 7:46 PM

😂 If $AUTL really dives to $1, I’ll liquidate everything and go all-in here. Net cash > mcap, approvals stacking, 52 US sites live. Shorts praying for $1 = pure comedy 🤡 🦍

1 · Reply

Ycapital Oct. 3 at 7:40 PM

🤌🏼 💎 $SLS $AUTL 💎

0 · Reply

Condemor Oct. 3 at 3:57 PM

$AUTL shorted 220k and will cover at 1.20 Meowwww

2 · Reply

Market Cap	428.49M
Revenue (ttm)	10.12M
Net Income (ttm)	-220.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,180.43%
Debt to Equity Ratio	0.00

Volume	2,735,100
Avg Vol	3,879,666
Day's Range	N/A - N/A
Shares Out	266.14M
Stochastic %K	60%
Beta	1.84
Analysts	Strong Sell
Price Target	$9.59